Skip to main content
SpringerLink
Log in

Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

The purpose of this study was to identify the common time point to achieve hydroxylation index (HI: omeprazole plasma concentration/5-hydroxyomeprazole plasma concentration) reflecting AUCOPZ/AUC5OH-OPZ after intravenous (IV) and oral (PO) administration.

Methods

Twenty young and 28 elderly healthy subjects, including different CYP2C19 genotypes, were enrolled in the study. The young subjects received either 40 mg PO or 20 mg IV omeprazole, whereas the elderly subjects received 10 mg IV. The relation between AUCOPZ/AUC5OH-OPZ and HI was determined by Spearman’s rank correlation. Multiple stepwise linear regression analysis was performed to identify the common time point to calculate HI that reflects AUCOPZ/AUC5OH-OPZ after IV.

Results

In the correlation between HI and AUCOPZ/AUC5OH-OPZ IV at observed time points, HI3h showed the highest correlation coefficients (r = 0.894, p < 0.001) in all 48 subjects. The correlation of HI between IV and PO at observed time points showed that HI3h was highest (r = 0.916, p < 0.001) in 20 young subjects. Additionally, there was no significant difference between HI3h of IV and that of PO (12.9 ± 15.9 and 12.9 ± 15.1, p = 0.997). The regression equation of HI3h was the best to estimate AUCOPZ/AUC5OH-OPZ (AUCOPZ/AUC5OH-OPZ = 1.37 • HI3h + 0.18 • Age – 7.83, r 2 = 0.883, p < 0.001).

Conclusions

This study demonstrated that HI3h after omeprazole IV was able to estimate AUCOPZ/AUC5OH-OPZ, as well as HI3h after PO. Additionally, CYP2C19 activity can be estimated more definitely by using HI after omeprazole IV without intestinal absorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Guerreiro AS, Neves BC, Quina MG (1990) Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists. Aliment Pharmacol Ther 4:309–313

    Article  PubMed  CAS  Google Scholar 

  2. Tybring G, Bottiger Y, Widen J, Bertilsson L (1994) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62:129–137

    Google Scholar 

  3. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422

    PubMed  Google Scholar 

  4. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, Bertilsson L (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511–518

    PubMed  CAS  Google Scholar 

  5. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552–561

    Article  PubMed  CAS  Google Scholar 

  6. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181–202

    Article  PubMed  CAS  Google Scholar 

  7. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552–561

    Article  PubMed  CAS  Google Scholar 

  8. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS Jr (2005) Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45:1413–1421

    Article  PubMed  CAS  Google Scholar 

  9. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517–528

    Article  PubMed  CAS  Google Scholar 

  10. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH (2001) Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 70:455–461

    PubMed  CAS  Google Scholar 

  11. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, Bertilsson L (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511–518

    PubMed  CAS  Google Scholar 

  12. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, Nakano S, Higuchi S (1996) Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19 m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59:647–653

    Article  PubMed  CAS  Google Scholar 

  13. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:558–563

    Article  Google Scholar 

  14. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6:547–551

    Article  PubMed  CAS  Google Scholar 

  15. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T (2005) The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44:1179–1189

    Article  PubMed  CAS  Google Scholar 

  16. Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T (2007) Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol 63:143–149

    Article  PubMed  CAS  Google Scholar 

  17. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–958

    Article  PubMed  CAS  Google Scholar 

  18. Lin JH, Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361–390

    Article  PubMed  CAS  Google Scholar 

  19. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598

    PubMed  Google Scholar 

  20. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113

    Article  PubMed  CAS  Google Scholar 

  21. Shimizu M, Uno T, Niioka T, Yaui-Furukori N, Takahata T, Sugawara K, Tateishi T (2006) Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 832:241–248

    Article  PubMed  CAS  Google Scholar 

  22. Landahl S, Andersson T, Larsson M, Lernfeldt B, Lundborg P, Regardh CG, Sixt E, Skanberg I (1992) Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet 23:469–476

    PubMed  CAS  Google Scholar 

  23. Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH (1997) Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 7:115–119

    Article  PubMed  CAS  Google Scholar 

  24. Andersson T (1991) Omeprazole drug interaction studies. Clin Pharmacokinet 21:195–212

    PubMed  CAS  Google Scholar 

  25. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9–28

    PubMed  CAS  Google Scholar 

  26. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T (2004) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487–494

    Article  PubMed  CAS  Google Scholar 

  27. Rinetti M, Regazzi MB, Villani P, Tizzoni M, Sivelli R (1991) Pharmacokinetics of omeprazole in cirrhotic patients. Arzneimittelforschung 41:420–422

    PubMed  CAS  Google Scholar 

  28. Andersson T, Olsson R, Regardh CG, Skanberg I (1993) Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet 24:71–78

    Article  PubMed  CAS  Google Scholar 

  29. Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, Sakai T, Otsubo K, Higuchi S (1999) Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 47:115–119

    Article  PubMed  CAS  Google Scholar 

  30. Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I (2005) In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol 45:1221–1229

    Article  PubMed  CAS  Google Scholar 

  31. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181–202

    Article  PubMed  CAS  Google Scholar 

  32. Pilbrant A, Cederberg C (1985) Development of an oral formulation of omeprazole. Scand J Gastroenterol 108(Suppl):113–120

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Hirosaki University Hospital, Hirosaki, Japan

    Takenori Niioka & Makoto Hayakari

  2. Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki, Japan

    Tsukasa Uno, Katsuyoshi Sugimoto & Tomonori Tateishi

  3. Department of Clinical Pharmacy, Aomori University Faculty of Pharmaceutical, Aomori, Japan

    Kazunobu Sugawara

  4. Department of Hospital Pharmacy, Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, 903-0215, Japan

    Tsukasa Uno

  5. Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki, 036-8562, Japan

    Tsukasa Uno

Authors
  1. Takenori Niioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsukasa Uno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsuyoshi Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunobu Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Hayakari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomonori Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsukasa Uno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niioka, T., Uno, T., Sugimoto, K. et al. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur J Clin Pharmacol 63, 1031–1038 (2007). https://doi.org/10.1007/s00228-007-0331-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0331-3

Keywords

Search

Navigation